Acelrx Pharmaceuticals Inc Net debt/EBITDA
Что обозначает Net debt/EBITDA в Acelrx Pharmaceuticals Inc?
Net debt/EBITDA Acelrx Pharmaceuticals Inc является 1.67
Какое определение для Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA компаний в Health Care сектор на NASDAQ по сравнению с Acelrx Pharmaceuticals Inc
Что делает Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Компании с net debt/ebitda похож на Acelrx Pharmaceuticals Inc
- ESI SA имеет Net debt/EBITDA из 1.66
- GB Plc имеет Net debt/EBITDA из 1.66
- Galway Metals имеет Net debt/EBITDA из 1.66
- N.V. Nederlandsche Apparatenfabriek Nedap имеет Net debt/EBITDA из 1.66
- Medallia Inc имеет Net debt/EBITDA из 1.67
- Energous Corp имеет Net debt/EBITDA из 1.67
- Acelrx Pharmaceuticals Inc имеет Net debt/EBITDA из 1.67
- Partners AG имеет Net debt/EBITDA из 1.67
- Scansource имеет Net debt/EBITDA из 1.67
- SenesTech Inc имеет Net debt/EBITDA из 1.68
- Northern Dynasty Minerals имеет Net debt/EBITDA из 1.68
- Petros Pharmaceuticals имеет Net debt/EBITDA из 1.69
- Caledonia Mining Plc имеет Net debt/EBITDA из 1.69